Adagio Medical (Nasdaq:ADGM) today announced new six-month results from its FULCRUM-VT clinical trial evaluating its ablation ...

In the single-arm FULCRUM-VT trial, 59% of patients remained free of recurrent VT at 6 months, with less amiodarone use.

Stereotactic arrhythmia radioablation reduces sustained ventricular tachycardia episodes and defibrillator shocks in patients with treatment-refractory disease, without treatment related deaths.

LAGUNA HILLS, Calif. - Adagio Medical Holdings Inc (NASDAQ:ADGM) announced today that the U.S. Food and Drug Administration has granted Investigational Device Exemption approval to expand the ...

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac ...

Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that the U.S.

MINNEAPOLIS and ATLANTA, April 16, 2026 /PRNewswire/ -- Francis Medical, Inc., a privately held medical device company, today announced the continued expansion of its U.S. commercial launch with the ...

Virtual replicas of individual patients’ hearts have allowed doctors to refine and personalize a lifesaving medical procedure for dangerous rhythm disturbances. Heart models may be just the leading ...

The trial is evaluating the vCLAS cryoablation system at 20 centres across Canada and the US.

Catheter ablation is an important treatment modality for patients with atrial fibrillation (AF). Although the superiority of catheter ablation over antiarrhythmic drug therapy has been demonstrated in ...

Adagio Medical Holdings, Inc. ADGM shares are up during Monday’s premarket session following the announcement of positive ...